428 assets in Triple-Negative Breast Carcinoma

Therapeutic assets addressing Triple-Negative Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Capivasertib Triple-Negative Breast Carcinoma	AstraZeneca	P3	BB (71)
Carboplatin Triple-Negative Breast Carcinoma	M.D. Anderson Cancer Center	P4	BB (71)
Cyclophosphamide Triple-Negative Breast Carcinoma	M.D. Anderson Cancer Center	P4	BB (70)
Veliparib Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P3	BB (69)
Atezolizumab Triple-Negative Breast Carcinoma	European Institute of Oncology	P3	BB (68)
Enzalutamide Triple-Negative Breast Carcinoma	Nuvation Bio Inc.	P2	BB (68)
Famitinib Triple-Negative Breast Carcinoma	Fudan University	P3	BB (68)
Alpelisib Triple-Negative Breast Carcinoma	The Methodist Hospital Research Institute	P3	BB (67)
Bicalutamide Triple-Negative Breast Carcinoma	Universitaire Ziekenhuizen KU Leuven	P3	BB (67)
Epirubicin Triple-Negative Breast Carcinoma	M.D. Anderson Cancer Center	P4	BB (67)
Adriamycin Triple-Negative Breast Carcinoma	Yuan Yuan	P3	BB (66)
Anti-Pd-L1 Monoclonal Antibody Shr-1316 Triple-Negative Breast Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	BB (66)
Binimetinib Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P2	BB (66)
Cis-Diamminedichloroplatinum Ii Triple-Negative Breast Carcinoma	Andrew Hantel, MD	P3	BB (66)
Pembrolizumab Triple-Negative Breast Carcinoma	M.D. Anderson Cancer Center	P3	BB (66)
Pertuzumab Triple-Negative Breast Carcinoma	Fudan University	P3	BB (66)
Ipilimumab Triple-Negative Breast Carcinoma	Emory University	P2	BB (65)
Ladiratuzumab Vedotin Triple-Negative Breast Carcinoma	Seagen Inc.	P2	BB (65)
Trastuzumab Deruxtecan Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P2	BB (65)
Amlodipine Triple-Negative Breast Carcinoma	The Methodist Hospital Research Institute	P2	BB (64)
Aspirin Triple-Negative Breast Carcinoma	The Methodist Hospital Research Institute	P2	BB (64)
Bebt-209 Capsules Triple-Negative Breast Carcinoma	BeBetter Med Inc	P2/3	BB (64)
Capecitabine Triple-Negative Breast Carcinoma	National University Hospital, Singapore	P3	BB (64)
Nivestim Triple-Negative Breast Carcinoma	MedSIR	P3	BB (64)
Omega-N-Methylarginine Triple-Negative Breast Carcinoma	The Methodist Hospital Research Institute	P2	BB (64)
Sargramostim Triple-Negative Breast Carcinoma	University of Washington	P2	BB (64)
Toripalimab Triple-Negative Breast Carcinoma	Nanjing Leads Biolabs Co.,Ltd	P3	BB (64)
Vinorelbine Ditartrate Triple-Negative Breast Carcinoma	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P3	BB (64)
Eribulin Monomethanesulfonate Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P3	B (63)
Fluorouracilum Triple-Negative Breast Carcinoma	Pfizer	P3	B (63)
Rivoceranib Triple-Negative Breast Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P3	B (63)
Celecoxib Triple-Negative Breast Carcinoma	Université de Sherbrooke	P2	B (62)
Docetaxel Triple-Negative Breast Carcinoma	BioLite, Inc.	P3	B (62)
Ivonescimab Triple-Negative Breast Carcinoma	Cedars-Sinai Medical Center	P3	B (62)
Olaparib Triple-Negative Breast Carcinoma	AHS Cancer Control Alberta	P3	B (62)
pm8002 Triple-Negative Breast Carcinoma	Biotheus Inc.	P3	B (62)
utd1 Triple-Negative Breast Carcinoma	Fudan University	P3	B (62)
Utidelone Triple-Negative Breast Carcinoma	Fudan University	P3	B (62)
Durvalumab Triple-Negative Breast Carcinoma	Queen Mary University of London	P2	B (61)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P2	B (61)
Pegfilgrastim Triple-Negative Breast Carcinoma	Yonsei University	P3	B (61)
Benmelstobart Triple-Negative Breast Carcinoma	Fudan University	P3	B (60)
Bet Bromodomain Inhibitor Zen-3694 Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Boserolimab Triple-Negative Breast Carcinoma	Merck Sharp & Dohme LLC	P2	B (60)
Catequentinib Triple-Negative Breast Carcinoma	Jiangsu Cancer Institute & Hospital	P3	B (60)
Cetuximab Triple-Negative Breast Carcinoma	Pfizer	P3	B (60)
Eribulin Triple-Negative Breast Carcinoma	Hu Hai	P3	B (60)
Everolimus Triple-Negative Breast Carcinoma	UNC Lineberger Comprehensive Cancer Center	P3	B (60)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide Triple-Negative Breast Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P3	B (60)
Ipatasertib Triple-Negative Breast Carcinoma	MedSIR	P3	B (60)

Showing 1 to 50 of 428 assets

PreviousPage 1 of 9Next